BBIO
BridgeBio Pharma, Inc. NASDAQ Listed Jun 27, 2019$67.48
Mkt Cap $13.1B
52w Low $31.77
67.2% of range
52w High $84.94
50d MA $71.21
200d MA $64.72
P/E (TTM)
-18.1x
EV/EBITDA
-25.6x
P/B
—
Debt/Equity
-1.3x
ROE
35.1%
P/FCF
-33.8x
RSI (14)
—
ATR (14)
—
Beta
1.09
50d MA
$71.21
200d MA
$64.72
Avg Volume
2.7M
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
421 Kipling Street · Palo Alto, CA 94301 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.70 | -0.84 | -20.0% | 67.45 | -1.4% | -0.1% | — | — | — | — | — |
| Feb 24, 2026 | AMC | -0.71 | -1.00 | -40.2% | 68.31 | +3.2% | -2.6% | -1.0% | -2.7% | -4.1% | -5.5% | — |
| Oct 29, 2025 | AMC | -0.88 | -0.95 | -8.0% | 66.62 | -0.8% | -4.9% | -6.0% | -7.0% | -7.9% | -5.9% | — |
| Aug 5, 2025 | AMC | -0.83 | -0.95 | -14.5% | 49.21 | -9.6% | -8.9% | -6.6% | -5.3% | -2.0% | -0.2% | — |
| Apr 29, 2025 | AMC | -1.00 | -0.88 | +12.0% | 36.42 | +6.0% | +5.3% | +5.4% | +5.9% | +4.9% | +1.4% | — |
| Feb 20, 2025 | AMC | -1.09 | -1.31 | -20.2% | 36.81 | +3.1% | +0.1% | -1.5% | -6.7% | -9.1% | -7.0% | — |
| Nov 12, 2024 | AMC | -1.03 | -0.86 | +16.5% | 24.62 | +1.2% | +0.7% | -2.1% | -3.7% | -9.2% | -8.4% | — |
| Aug 1, 2024 | AMC | -1.09 | -1.02 | +6.4% | 26.18 | -6.6% | +0.0% | -2.6% | -5.0% | -8.6% | -6.5% | — |
| May 2, 2024 | AMC | -0.40 | -0.05 | +87.5% | 27.74 | +2.6% | +0.3% | +1.3% | +0.2% | -0.1% | +3.6% | — |
| Feb 22, 2024 | AMC | -0.95 | -0.96 | -1.1% | 33.60 | +2.2% | +1.2% | +3.8% | +6.3% | +5.0% | +1.6% | — |
| Nov 2, 2023 | AMC | -0.86 | -1.08 | -25.6% | 26.92 | +2.4% | +7.1% | +3.6% | +9.2% | +9.2% | +0.6% | — |
| Aug 3, 2023 | AMC | -0.86 | -0.98 | -14.0% | 32.10 | +2.0% | -2.6% | -3.6% | +0.5% | -1.3% | +0.9% | — |
| May 4, 2023 | AMC | -0.84 | -0.92 | -9.5% | 13.50 | -2.7% | +1.3% | +0.1% | +1.9% | +2.4% | +5.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Truist | Maintains | Buy → Buy | — | $69.71 | $68.35 | -2.0% | +1.8% | +2.0% | -1.6% | -1.0% | -1.3% |
| Apr 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.71 | $68.35 | -2.0% | +1.8% | +2.0% | -1.6% | -1.0% | -1.3% |
| Apr 28 | Mizuho | Maintains | Outperform → Outperform | — | $74.52 | $83.20 | +11.6% | -6.5% | -4.8% | -4.6% | -8.0% | -7.4% |
| Apr 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $73.28 | $75.86 | +3.5% | +1.7% | -4.9% | -3.2% | -3.0% | -6.4% |
| Mar 18 | Mizuho | Maintains | Outperform → Outperform | — | $70.94 | $70.94 | +0.0% | -1.2% | -1.2% | -3.4% | -1.9% | -3.4% |
| Mar 10 | JP Morgan | Maintains | Overweight → Overweight | — | $65.64 | $66.12 | +0.7% | +13.2% | +8.8% | +3.6% | +5.7% | +8.2% |
| Feb 25 | Truist | Maintains | Buy → Buy | — | $68.31 | $70.50 | +3.2% | -2.6% | -1.0% | -2.7% | -4.1% | -5.5% |
| Feb 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $68.31 | $70.50 | +3.2% | -2.6% | -1.0% | -2.7% | -4.1% | -5.5% |
| Feb 25 | Morgan Stanley | Maintains | Overweight → Overweight | — | $68.31 | $70.50 | +3.2% | -2.6% | -1.0% | -2.7% | -4.1% | -5.5% |
| Feb 25 | Evercore ISI | Maintains | Outperform → Outperform | — | $68.31 | $70.50 | +3.2% | -2.6% | -1.0% | -2.7% | -4.1% | -5.5% |
| Feb 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $75.25 | $74.31 | -1.2% | +0.8% | -1.8% | -6.0% | -9.4% | -9.8% |
| Feb 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $76.06 | $77.55 | +2.0% | -1.1% | -0.3% | -2.8% | -7.0% | -10.4% |
| Feb 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $76.06 | $77.55 | +2.0% | -1.1% | -0.3% | -2.8% | -7.0% | -10.4% |
| Jan 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $76.26 | $74.55 | -2.2% | +1.2% | +2.5% | +4.8% | +2.1% | +2.0% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $74.27 | $73.55 | -1.0% | -0.6% | +4.0% | +3.5% | +6.5% | +4.9% |
| Dec 15 | Leerink Partners | Maintains | Outperform → Outperform | — | $75.15 | $74.96 | -0.3% | -0.9% | +0.7% | -1.5% | -1.3% | +1.5% |
| Nov 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $62.81 | $63.12 | +0.5% | +6.0% | +5.4% | +3.6% | +5.7% | +6.5% |
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $62.73 | $62.73 | +0.0% | -1.5% | +0.1% | +6.1% | +5.6% | +3.7% |
| Nov 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.64 | $62.74 | +0.2% | -1.1% | -2.0% | +0.0% | +0.1% | -1.3% |
| Oct 31 | Goldman Sachs | Maintains | Buy → Buy | — | $63.37 | $63.88 | +0.8% | -1.2% | -2.2% | -3.2% | -1.1% | -1.0% |
| Oct 30 | TD Cowen | Maintains | Buy → Buy | — | $66.62 | $66.07 | -0.8% | -4.9% | -6.0% | -7.0% | -7.9% | -5.9% |
| Oct 30 | Truist | Maintains | Buy → Buy | — | $66.62 | $66.07 | -0.8% | -4.9% | -6.0% | -7.0% | -7.9% | -5.9% |
| Oct 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $66.62 | $66.07 | -0.8% | -4.9% | -6.0% | -7.0% | -7.9% | -5.9% |
| Oct 30 | Raymond James | Maintains | Outperform → Outperform | — | $66.62 | $66.07 | -0.8% | -4.9% | -6.0% | -7.0% | -7.9% | -5.9% |
| Oct 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $66.62 | $66.07 | -0.8% | -4.9% | -6.0% | -7.0% | -7.9% | -5.9% |
| Oct 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $64.50 | $69.37 | +7.6% | +3.3% | -1.8% | -2.9% | -3.9% | -4.9% |
| Oct 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $54.26 | $57.00 | +5.0% | +17.1% | +18.9% | +22.8% | +16.8% | +15.4% |
| Oct 21 | Raymond James | Maintains | Outperform → Outperform | — | $56.26 | $56.21 | -0.1% | -3.4% | -5.4% | -4.4% | -3.6% | +13.0% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $51.21 | $51.08 | -0.3% | +0.5% | +0.5% | -0.1% | +4.1% | +2.3% |
| Sep 12 | UBS | Maintains | Buy → Buy | — | $52.60 | $52.91 | +0.6% | -2.6% | -2.1% | -2.1% | -2.7% | +1.4% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.00 | $50.06 | +0.1% | +3.7% | +3.7% | +6.8% | +8.6% | +7.0% |
| Sep 3 | JP Morgan | Maintains | Overweight → Overweight | — | $50.00 | $50.06 | +0.1% | +3.7% | +3.7% | +6.8% | +8.6% | +7.0% |
| Aug 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.57 | $52.49 | -0.2% | -1.5% | -4.9% | -1.4% | -1.4% | +1.5% |
| Aug 8 | JP Morgan | Maintains | Overweight → Overweight | — | $45.95 | $45.64 | -0.7% | +1.4% | +5.0% | +6.8% | +9.6% | +11.4% |
| Aug 6 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $49.21 | $44.50 | -9.6% | -8.9% | -6.6% | -5.3% | -2.0% | -0.2% |
| Aug 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $49.21 | $44.50 | -9.6% | -8.9% | -6.6% | -5.3% | -2.0% | -0.2% |
| Jul 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $46.23 | $46.53 | +0.6% | +0.2% | -1.3% | +2.2% | +2.5% | +3.3% |
| Jul 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $46.47 | $47.34 | +1.9% | +2.6% | +1.1% | +1.4% | +0.6% | +0.1% |
| Jul 11 | Citigroup | Maintains | Buy → Buy | — | $46.27 | $45.98 | -0.6% | +0.4% | +3.1% | +1.5% | +1.8% | +1.0% |
| Jul 9 | Oppenheimer | Upgrade | Perform → Outperform | — | $43.19 | $44.26 | +2.5% | +6.5% | +7.1% | +7.6% | +10.4% | +8.8% |
| Jun 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $44.86 | $45.13 | +0.6% | -3.7% | -4.6% | -4.5% | -1.9% | -3.0% |
| Jun 25 | BofA Securities | Maintains | Buy → Buy | — | $44.45 | $44.78 | +0.7% | -0.2% | +1.5% | +0.9% | -2.9% | -3.8% |
| Jun 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.62 | $39.46 | +2.2% | +1.1% | +3.8% | +1.1% | +2.7% | +3.0% |
| Apr 30 | UBS | Maintains | Buy → Buy | — | $36.42 | $38.61 | +6.0% | +5.3% | +5.4% | +5.9% | +4.9% | +1.4% |
| Apr 30 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $36.42 | $38.61 | +6.0% | +5.3% | +5.4% | +5.9% | +4.9% | +1.4% |
| Apr 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $36.42 | $38.61 | +6.0% | +5.3% | +5.4% | +5.9% | +4.9% | +1.4% |
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.85 | $34.58 | -0.8% | -1.8% | -2.9% | -2.8% | -3.8% | -1.9% |
| Mar 24 | JP Morgan | Maintains | Overweight → Overweight | — | $34.77 | $35.10 | +0.9% | +7.0% | +5.7% | +3.8% | +4.7% | +1.0% |
| Feb 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $36.81 | $37.94 | +3.1% | +0.1% | -1.5% | -6.7% | -9.1% | -7.0% |
| Feb 21 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $36.81 | $37.94 | +3.1% | +0.1% | -1.5% | -6.7% | -9.1% | -7.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | Apuli MaricelOff | Chief Accounting Officer | Sell | 2,000 | $71.58 | $143K | 134,115 | -0.30% | — |
8-K · 1.02
!! High
BridgeBio Pharma, Inc. -- 8-K 1.02: Material Agreement Terminated
I cannot determine the termination reason (breach, mutual, regulatory, or expiration) from the information provided, so I cannot accurately explain investor implications without speculating.
May 8
8-K · 7.01
! Medium
BridgeBio Oncology Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
BridgeBio Oncology announced leadership transitions on April 22, 2026, which could signal strategic shifts affecting company direction and investor confidence.
Apr 23
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
BridgeBio's positive Phase 3 data for BBP-418 and anticipated FDA approval in late 2026/early 2027 could validate a potentially first-in-class rare disease treatment, significantly boosting revenue growth if commercialization succeeds.
Mar 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Kumar's departure as CEO of BridgeBio Oncology signals potential leadership instability at the oncology subsidiary, which could impact clinical trial progress and investor confidence in the parent company's pipeline.
Mar 25
8-K
BridgeBio Pharma, Inc. -- 8-K Filing
BridgeBio plans to submit an NDA for encaleret in late 2025/early 2026 following positive Phase 3 results, targeting a market launch in late 2026 or early 2027.
Feb 24
8-K · 8.01
!! High
BridgeBio Pharma, Inc. -- 8-K 8.01: Material Event / Announcement
BridgeBio Pharma's infigratinib achieved statistical significance in Phase 3 achondroplasia trials for body proportionality improvements, potentially supporting a future regulatory submission for this genetic disorder treatment.
Feb 12
Data updated apr 24, 2026 8:42pm
· Source: massive.com